Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

doi:10.1158/1078-0432.CCR-17-2398

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2018

Horn Leora, Infante Jeffrey R, Reckamp Karen L, Blumenschein George R, Leal Ticiana A, Waqar Saiama N, Gitlitz Barbara J, Sanborn Rachel E, Whisenant Jennifer G, Du Liping, Neal Joel W, Gockerman Jon P, Dukart Gary, Harrow Kimberly, Liang Chris, Gibbons James J, Holzhausen Allison, Lovly Christine M, Wakelee Heather A

Abstract excerpt

Purpose: Evaluate safety and determine the recommended phase II dose (RP2D) of ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), and evaluate preliminary pharmacokinetics and antitumor activity in a first-in-human, phase I/II clinical trial primarily in patients with non-small cell lung cancer (NSCLC).Patients and Methods: In dose escalation, ensartinib was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Kaplan-Meier Estimate

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Pyridazines

Source

Open in PubMed Open full text

Identifiers

PMID: 29563138
DOI: 10.1158/1078-0432.CCR-17-2398
PMCID: PMC6004248

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.PMID 29563138Read ↗

Efficacy and Safety of Ensartinib in the Treatment of Non-Small Cell Lung Cancer: A Systematic Review of Clinical TrialsSemantic proximity Read ↗

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.Semantic proximity Read ↗

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.Semantic proximity Read ↗

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report.Semantic proximity Read ↗

A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.Semantic proximity Read ↗

Efficacy and safety of aumolertinib/icotinib combination therapy for naive EGFR-mutant non-small-cell lung cancer patients with brain metastases: A phase I/II study.Semantic proximity Read ↗

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.Semantic proximity Read ↗

Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.Semantic proximity Read ↗

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.